Vertex Pharmaceuticals Inc. | Ownership
Companies that own Vertex Pharmaceuticals Inc.
T. Rowe Price Associates, Inc.
25,643,662
10.02%
-1,925,016
0.64%
06/30/2018
The Vanguard Group, Inc.
18,173,071
7.11%
238,776
0.11%
06/30/2018
Fidelity Management & Research Co.
15,588,305
6.1%
-897,998
0.28%
06/30/2018
BlackRock Fund Advisors
12,862,197
5.03%
-1,217,331
0.12%
06/30/2018
Capital Research & Management Co. (World Investors)
10,992,034
4.3%
1,993,107
0.28%
06/30/2018
SSgA Funds Management, Inc.
10,489,544
4.11%
455,166
0.15%
06/30/2018
Wellington Management Co. LLP
10,308,399
4.03%
-767,106
0.36%
06/30/2018
ClearBridge Investments LLC
6,000,467
2.35%
-390,259
0.95%
06/30/2018
Jennison Associates LLC
5,063,007
1.98%
-1,712,321
0.8%
06/30/2018
JPMorgan Investment Management, Inc.
4,966,915
1.94%
-976,193
0.3%
06/30/2018
| Address |
50 Northern Avenue
Boston Massachusetts 02210
United States
|
|
Employees
|
- |
| Website |
http://www.vrtx.com |
| Updated |
07/08/2019 |
| Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis. The company was founded by Joshua S. |
